If you have been reading about prothymosin alpha and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
== The Establishment of Institute of Biological Chemistry, Academia Sinica == Despite his significant scientific achievements, Dr. Li was also dedicated to the initiation and development of protein research in Taiwan. In spring 1958, Dr. Li was invited by Dr. Shih Hu to lecture a three-week course regarding the newly developed technology in protein chemistry and his latest pituitary gland research at National Taiwan University with the support from China Foundation for the Promotion of Education and Culture. At that time, the academic community only knew that protein research was developing rapidly abroad and a scholar had already made extraordinary achievements, and so when Dr. Li introduced the first-hand knowledge, it really attracted and inspired domestic scientists. Dr. Li believed that the protein chemistry was the foundation of future biochemical and biological sciences research, so he decided to assist the establishment of domestic protein research institute. In order to cultivate talents in Taiwan, Dr. Li personally provided scholarships and selected and persuaded scholars who have settled in Taiwan to continue the research in his or other research institutes. With the support from Academia Sinica, National Science Council, Ministry of Education, and National Taiwan University, Institute of Biological Chemistry and Institute of Biochemical Sciences, College of Life Science, National Taiwan University were established in 1972.
=== Multidisciplinary doctoral programme === Has been instituted for students who have completed masters in any relevant discipline of natural sciences, medicine, engineering and other related sciences. RCB recruits Junior Research Fellowships (JRFs) twice during an academic year and already mentors 31 Research Fellows.
=== Biological detection === The discovery of radiative recombination in aluminum gallium nitride (AlGaN) alloys by U.S. Army Research Laboratory (ARL) led to the conceptualization of UV light-emitting diodes (LEDs) to be incorporated in light-induced fluorescence sensors used for biological agent detection. In 2004, the Edgewood Chemical Biological Center (ECBC) initiated the effort to create a biological detector named TAC-BIO. The program capitalized on semiconductor UV optical sources (SUVOS) developed by the Defense Advanced Research Projects Agency (DARPA). UV-induced fluorescence is one of the most robust techniques used for rapid real-time detection of biological aerosols. The first UV sensors were lasers lacking in-field-use practicality. In order to address this, DARPA incorporated SUVOS technology to create a low-cost, small, lightweight, low-power device. The TAC-BIO detector's response time was one minute from when it sensed a biological agent. It was also demonstrated that the detector could be operated unattended indoors and outdoors for weeks at a time. Aerosolized biological particles fluoresce and scatter light under a UV light beam. Observed fluorescence is dependent on the applied wavelength and the biochemical fluorophores within the biological agent. UV induced fluorescence offers a rapid, accurate, efficient and logistically practical way for biological agent detection.
For services to Cricket. Richard Broyd, OBE. Philanthropist. For services to Heritage and Conservation. James Alexander Bullion. Lately Executive Director, Adult Social Services, Norfolk County Council and lately President, Association of Directors of Adult Social Services. For services to Social Care. Robert Geoffrey Burrow, MBE. For services to Motor Neurone Disease Awareness. William Morris Bush. Senior Adviser, Premier League. For services to Sport. Dr. Denise Marie Chaffer. Lately Director, Safety and Learning, NHS Resolution and lately President of the Royal College of Nursing. For services to Patient Safety. Dr. Jung Chang. Author. For services to Literature and to History. David George Crozier. Lately Head, Strategic Partnerships and Engagement, Queen's University Belfast. For services to the Economy. Mark Cutifani. Lately Chief Executive, Anglo American. For services to Investment in the Global Mining Industry. Huw Charles Davies. Lately Chief Executive, British Association for Supported Employment. For services to Employment for Disabled People. Mark William Davies. Director, Windsor Framework Taskforce, Cabinet Office. For Public Service. Dr. Laura Miranda Dawson (Laura Gilbert). Director, Data Science, Prime Minister's Office. For services to Technology and Analysis. Richard George Deverell. Director, Royal Botanic Gardens, Kew. For services to Botanical Science and Conservation. Professor Philip John Diamond. Director General, Square Kilometre Array Observatory. For services to Global Radio Astronomy. Catherine Jane Uttley Dovey.
Sources: en.wikipedia.org
== Alternative Medical Causes of Altered Turgor == Altered skin turgor can be caused by chronic medical conditions completely unrelated to an individual's immediate hydration status. Systemic sclerosis, or scleroderma, is an autoimmune disorder that triggers excessive collage production, resulting in abnormally tight, hard, and shiny skin that exhibits high turgor and cannot be pinched at all. On the other hand, genetic connective tissue disorders can drastically lower baseline skin tension, making the skin hyper-elastic. Additionally, localized fluid retention or severe edema stretches the dermis tightly, masking underlying systemic dehydration by artificially inflating skin turgor measurements.
=== Anti-inflammatory effects === The role of inflammation and the immune system in depression has been extensively studied. The evidence supporting this link has been shown in numerous studies over the past decade. Nationwide studies and meta-analyses of smaller cohort studies have uncovered a correlation between pre-existing inflammatory conditions such as type 1 diabetes, rheumatoid arthritis (RA), or hepatitis, and an increased risk of depression. Data also shows that using pro-inflammatory agents in the treatment of diseases like melanoma can lead to depression. Several meta-analytical studies have found increased levels of proinflammatory cytokines and chemokines in depressed patients. This link has led scientists to investigate the effects of antidepressants on the immune system. SSRIs were originally invented to increase levels of available serotonin in the extracellular spaces. However, the delayed response between when patients first begin SSRI treatment to when they see effects has led scientists to believe that other molecules are involved in the efficacy of these drugs. To investigate the apparent anti-inflammatory effects of SSRIs, both Kohler et al. and Więdłocha et al. conducted meta-analyses which have shown that after antidepressant treatment the levels of cytokines associated with inflammation are decreased. A large cohort study conducted by researchers in the Netherlands investigated the association between depressive disorders, symptoms, and antidepressants with inflammation.
== External links == "Datopotamab Deruxtecan (Code C151967)". NCI Thesaurus. Clinical trial number NCT05104866 for "A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)" at ClinicalTrials.gov Clinical trial number NCT04484142 for "Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)" at ClinicalTrials.gov Clinical trial number NCT04656652 for "Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)" at ClinicalTrials.gov Clinical trial number NCT05374512 for "A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)" at ClinicalTrials.gov
=== Biosynthesis === The biosynthetic route of curcumin is uncertain. In 1973, Peter J. Roughley and Donald A. Whiting proposed two mechanisms for curcumin biosynthesis. The first mechanism involves a chain extension reaction by cinnamic acid and 5 malonyl-CoA molecules that eventually arylize into a curcuminoid. The second mechanism involves two cinnamate units coupled together by malonyl-CoA. Both use cinnamic acid as their starting point, which is derived from the amino acid phenylalanine. Plant biosynthesis starting with cinnamic acid is rare compared to the more common p-coumaric acid. Only a few identified compounds, such as anigorufone and pinosylvin, build from cinnamic acid.
== F == Finegoldia magna Francisella tularensis (formerly Pasteurella tularensis) Fusobacterium Fusobacterium necrophorum Fusobacterium nucleatum (formerly Corynebacterium fusiforme) Frateuria aurantia (formerly Acetobacter aurantius)
Sources: en.wikipedia.org
=== Inflammation === Antalarmin has also been used extensively to study the role of CRH in inflammation. Intraperitoneal (i.p.) administration of antalarmin in rats significantly inhibited the inflammation caused by subcutaneous administration of carrageenan (a known inflammatory food additive) as measured by leukocyte concentrations. In a rat skin mast cell activation model, pre-treatment with Antalarmin (10 mg/kg, i.v.) inhibited the CRH-stimulated induction of mast cell degranulation, suggesting pro-inflammatory properties of CRH. Antalarmin also blocked the vascular permeability and mast cell degranulation response induced by intradermal Urocortin (10 nM). Collectively, these results indicate that during stress, CRH leads to the activation of skin mast cells through the CRH1 receptor which triggers vasodilation and increased vascular permeability. Chronic antalarmin treatment also showed anti-inflammatory effects and has been suggested as having potential uses in the treatment of inflammatory conditions such as arthritis, as well as stress-induced gastrointestinal ulcers and irritable bowel syndrome.
While this specific produce is not native to India and is harvested only once only during winter, the success of cold-chain intervention has made potatoes available all through the year and is now considered part of the country's staple diet. In the previous two decades, India has been developing at a quick pace and an increasing demand for high-value foods with a shift towards horticultural crops has been documented. This, coupled with rapid urbanisation resulted in multi-fold changes to the spending and consumption pattern of India's population. The existing food supply chain systems were unable to cope with these fast-changing demographic trends and the lack of efficient and effective supply chains is understood to lead to a variety of losses in the perishable food segment. In 2012, Indian farmers produced 240 million metric tonnes of horticultural produce, almost equal to its grain and cereals production. Various reports indicated that 18% to 40% of this produce was lost due to supply chain inefficiencies, concluding that a focused effort was required to promote the development of the cold-chain in the country. The Indian government and its Planning Commission spelt out clear intention, that cold-chain has to be supported. Amongst the core identified development areas are the base infrastructure, environmentally friendly technologies, standards, and protocols, enabling policies and specialised skills.
Dehydrated eggs advertisements appeared in the late 1890s in the United States. Powdered eggs appear in literature as a staple of camp cooking at least as early as 1912. Powdered eggs, known also as dried eggs, were widely used in the United Kingdom during World War II when food (including both fresh and dried eggs) was rationed. While nutritious, they were not a culinary treat; Esther Rantzen, reminiscing about the time, wrote that there were few real eggs, and "I can still remember the disgusting taste of powdered egg". It was also part of military rations. Bob Hope joked during a USO show, "Fellows, the folks at home are having a terrible time about eggs. They can't get any powdered eggs at all. They've got to use the old-fashioned kind you break open".
The Schengen rules do not require any other procedures; thus, the Schengen states are free to regulate further details on the content of the registration forms, and identity documents which are to be produced, and may also require the persons exempted from registration by Schengen laws to be registered. A Schengen state is also permitted to reinstate border controls with another Schengen country for a short period where there is a serious threat to that state's "public policy or internal security" or when the "control of an external border is no longer ensured due to exceptional circumstances". When such risks arise out of foreseeable events, the state in question must notify the European Commission in advance and consult with other Schengen states. Since the implementation of the Schengen Agreement, this provision has been invoked frequently by member states, especially in response to the European migrant crisis.
=== Micelles and dendrimers === Another type of drug delivery vehicle used is polymeric micelles. They are prepared from certain amphiphilic co-polymers consisting of both hydrophilic and hydrophobic monomer units. They can be used to carry drugs that have poor solubility. This method offers little in the terms of size control or function malleability. Techniques that utilize reactive polymers along with a hydrophobic additive to produce a larger micelle that create a range of sizes have been developed. Dendrimers are also polymer-based delivery vehicles. They have a core that branches out in regular intervals to form a small, spherical, and very dense nanocarrier.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.